HOME >> MEDICINE >> NEWS
Iressa news backgrounder

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we would have liked
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Iressa news backgrounder

(Date:3/29/2015)... Final Cut Pro X ... Film Studios, entitled TranSports. , “TranSports is a ... Cut Pro X,” said Christiana Austin, CEO of Pixel ... to effortlessly transition using this cool sports transition tool.” ... uniquely styled transition pack for Final Cut Pro X. ...
(Date:3/28/2015)... Coffee could not only perk you up in ... disease, researchers have found. , They found that those who ... antioxidants. Antioxidants fight gum disease. Does coffee, then, help fight ... Henry M. Goldman School of Dental Medicine explored in a ... the Journal of Periodontology. , “This is the first long-term ...
(Date:3/28/2015)... March 28, 2015 With more ... the fields of osteoporosis, osteoarthritis and musculoskeletal diseases ... it may be the first time in the ... forum that the hot-button topic is an emerging ... the well-accepted scientific principles of Wolff’s law, osteogenic ...
(Date:3/28/2015)... India Network visitor health insurance announced ... visitors who purchase the plan before arrival in the ... purchase the insurance program as soon as travel plans ... pre-existing medical conditions. Parents and grandparents traveling from India ... serious consequences to their health. Many visitors may not ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
(Date:3/27/2015)... BioCorRx, Inc. ( BICX ... is a healthcare solutions organization, which focuses solely on ... billion in the U.S. alone. The Company created a unique ... a specially compounded form for outpatient surgical implantation. The Company ... New Zealand ) to the specially formulated ...
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
(Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
Cached News: